These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 7405746)

  • 1. Approaches to drug selectivity in cancer therapy on the basis of differences between membranes of normal vs. neoplastic cells.
    Bertino JR
    Adv Pathobiol; 1980; 7():377-86. PubMed ID: 7405746
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent concepts on the mechanism of action of methotrexate.
    White JC
    Cancer Treat Rep; 1981; 65 Suppl 1():3-12. PubMed ID: 7326663
    [No Abstract]   [Full Text] [Related]  

  • 3. Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal Foundation Award Lecture.
    Bertino JR
    Cancer Res; 1979 Feb; 39(2 Pt 1):293-304. PubMed ID: 310709
    [No Abstract]   [Full Text] [Related]  

  • 4. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of methotrexate, aminopterin, and methasquin and inhibition of dihydrofolate reductase and of DNA synthesis in mouse small intestine.
    Philips FS; Sirotnak FM; Sodergren JE; Hutchison DJ
    Cancer Res; 1973 Jan; 33(1):153-8. PubMed ID: 4682318
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison of 4-amino-4-deoxy-N10-methylpteroic acid and methotrexate transport by mouse leukemia cells.
    Kessel D
    Mol Pharmacol; 1969 Jan; 5(1):21-5. PubMed ID: 5392912
    [No Abstract]   [Full Text] [Related]  

  • 7. Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity.
    May C; James RI; Gunther R; McIvor RS
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1444-51. PubMed ID: 8819532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
    Zhao R; Gao F; Babani S; Goldman ID
    Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic mice expressing the tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate.
    James RI; May C; Vagt MD; Studebaker R; McIvor RS
    Exp Hematol; 1997 Nov; 25(12):1286-95. PubMed ID: 9357973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antifol therapy: observations on the development of resistant L1210 leukemic cells in vivo.
    Browman GP; Lazarus H
    Cancer Treat Rep; 1980; 64(2-3):231-6. PubMed ID: 7407755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches to chemotherapy.
    Hutchison DJ
    Ann N Y Acad Sci; 1971 Nov; 186():496-500. PubMed ID: 5002440
    [No Abstract]   [Full Text] [Related]  

  • 12. New approaches to chemotherapy with folate antagonists: use of leucovorin "rescue" and enzymic folate depletion.
    Bertino JR; Levitt M; McCullough JL; Chabner B
    Ann N Y Acad Sci; 1971 Nov; 186():486-95. PubMed ID: 4943812
    [No Abstract]   [Full Text] [Related]  

  • 13. Resistance mechanisms to methotrexate in tumors.
    Bertino JR; Göker E; Gorlick R; Li WW; Banerjee D
    Stem Cells; 1996 Jan; 14(1):5-9. PubMed ID: 8820944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mechanism of action of methotrexate. I. Interaction with a low-affinity intracellular site required for maximum inhibition of deoxyribonucleic acid synthesis in L-cell mouse fibroblasts.
    Goldman ID
    Mol Pharmacol; 1974 Mar; 10(2):257-74. PubMed ID: 4859542
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane transport of methotrexate in human lymphoblastoid cells.
    Warren RD; Nichols AP; Bender RA
    Cancer Res; 1978 Mar; 38(3):668-71. PubMed ID: 304761
    [No Abstract]   [Full Text] [Related]  

  • 17. Cellular aspects of folate and antifolate membrane transport.
    Brzezińska A; Wińska P; Balińska M
    Acta Biochim Pol; 2000; 47(3):735-49. PubMed ID: 11310973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate and aminopterin lack in vivo antimalarial activity against murine malaria species.
    Irungu B; Kiboi D; Langat B; Rukunga G; Wittlin S; Nzila A
    Exp Parasitol; 2009 Oct; 123(2):118-21. PubMed ID: 19527714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-phase cells of rapidly growing and resting populations. Differences in response to methotrexate.
    Hryniuk WM; Fischer GA; Bertino JR
    Mol Pharmacol; 1969 Nov; 5(6):557-64. PubMed ID: 5392913
    [No Abstract]   [Full Text] [Related]  

  • 20. The cellular pharmacology of methotrexate.
    Goldman ID; Matherly LH
    Pharmacol Ther; 1985; 28(1):77-102. PubMed ID: 2414788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.